Greenridez 2.0 Acquisitions Corp. confirmed Friday that it has completed its acquisition of psychedelic research company Lophos Pharma, which is primarily concentrated on new therapeutic treatments derived from Peyote (Lophophora williamsii).
The Toronto-based company confirmed that it supports Lophos Pharma’s belief in Peyote’s potential to treat indications ranging from weight loss and addiction to anxiety and depression.
Following the acquisition, Greenridez will be operating under the name Lophos Holdings and has appointed Claire Stawnyczy as CEO. Prior to joining the marijuana industry in 2017, Stawnyczy previously worked in the biotechnology space.
During her time as CEO of Canalytica Corp., a business management and regulatory consulting firm, she led numerous licensed producers toward achieving regulatory compliance and streamlining business operations.
“I look forward to leading the Lophos team and respectfully adding to Peyote’s proud history,” said Stawnyczy. “We are excited by Health Canada’s recent amendment to the special access program and look forward to supplying patients in the future.”
Recent news in the psychedelics industry:
Promising Psychedelic Therapy Legislation Set To Make Waves In 2022
Photo: Courtesy of YubKooka via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
